All In Biotech

Drug Trial Radar · NCT06341621

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

A Prospective, Randomized, Open-label, Multicenter Phase III Study to Explore Chemotherapy Omission in ER+/HER2-endocrine-sensitive Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Last checked: Nov 20, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,900

Planned (sponsor's estimate)

Start

Apr 2, 2024

Primary completion

Feb 25, 2027

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in ER+/HER2-endocrine-sensitive breast cancer with 1-3 positive lymph nodes receiving extended (3 year) adjuvant abemaciclib

Conditions

  • Breast Cancer

Interventions

  • 3-year abemaciclib without chemoDrug

    aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.

  • treatment of physician's choiceDrug

    treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease free survivalTime frame: 5 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhimin Cancer Shao

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.